Inovio Pharmaceuticals Inc. Watch

from 10-K 2 pages Appendix a Inovio Pharmaceuticals, Inc. Severance Plan Participation Agreement

from 10-K 2 pages Appendix a Inovio Pharmaceuticals, Inc. Severance Plan Participation Agreement

from 10-K 2 pages Appendix a Inovio Pharmaceuticals, Inc. Severance Plan Participation Agreement

from 10-K 14 pages Inovio Pharmaceuticals, Inc. Severance Plan and Summary Plan Description Approved by the Board of Directors

from 10-K 3 pages First Amendment to the Amended and Restated License and Collaboration Agreement

from 10-Q 6 pages Inovio Pharmaceuticals, Inc. Rsu Award Grant Notice

from 10-Q 7 pages Inovio Pharmaceuticals, Inc. Stock Option Grant Notice

from 8-K 27 pages Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan Adopted by the Board of Directors: March 24, 2023 Approved by Stockholders: May 16, 2023 Inovio Pharmaceuticals, Inc. 2023 Omnibus Incentive Plan

from 10-Q 8 pages 1.separation. You and the Company Have Mutually Agreed That Your Employment With the Company Will End on May 10, 2022 (The “Separation Date”), And, to the Extent Applicable, Have Agreed to Waive Any Advance Notice Requirement Under Your Employment Agreement With the Company, Dated as of March 31, 2008, as Amended (The “Employment Agreement”) or Otherwise. You and the Company Agree That Upon the Later of (X) 4:15 P.M. on Tuesday, May 10, 2022; or (Y) Immediately After the Company Files SEC Form 10q for the Quarter Ending March 31, 2022 With the Securities Exchange Commission, You Will Be Deemed to Have Resigned From Your Roles as an Officer of the Company, as a Member of the Company’s Board of Directors (The “Board”) and From Any Other Positions You Hold With the Company and/or Any of Its Affiliates. You Agree to Complete Such Documentation as May Be Reasonably Requested by the Company to Effect Your Resignation From These Positions. You Further Agree That Within Five (5) Days After the Separation Date, You Will Notify the Board of Directors of Geneos Therapeutics (The “Geneos Board”) of Your Departure From the Company and That You Will No Longer Serve as the Company’s Representative on the Geneos Board

from 10-Q 34 pages Inovio Pharamceuticals, Inc. Common Stock, $0.001 Par Value Atm Equity Offeringsm Sales Agreement

from 10-Q 75 pages Amended and Restated Collaboration and License Agreement

from 10-K 63 pages Collaboration and License Agreement

from 10-Q 26 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It (I) Is Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed

from 10-Q 28 pages Certain Confidential Portions of This Exhibit Have Been Omitted and Replaced With “[***]”. Such Identified Information Has Been Excluded From This Exhibit Because It (I) Is Not Material and (II) Would Likely Cause Competitive Harm to the Company if Disclosed

from 10-K 11 pages Employment Agreement

from 10-K 11 pages Employment Agreement

from 8-K 17 pages Inovio Pharmaceuticals, Inc. Krw4,700,000,000 1.00% Convertible Bonds Due 2024 Registration Rights Agreement

from 8-K 26 pages Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan Adopted by the Board of Directors: March 9, 2016 Approved by Stockholders: May 13, 2016 Amended by the Board of Directors: March 21, 2019 Approved by Stockholders: May 8, 2019 Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan

from 10-Q 25 pages 1. Separation. in Accordance With Section 7(c) of Your Employment Agreement, Dated as of December 10, 2009 (As Amended, the “Employment Agreement”), the Company Provided You, by Letter Dated March 6, 2019, With Thirty (30) Days’ Prior Written Notice of Your Termination From the Company. Accordingly, Your Last Day of Employment Will Be April 5, 2019 (The “Separation Date”)

from 10-K 12 pages Consulting Agreement